Interleukin-12 message in a bottle

IL12 is a very potent cancer immunotherapy agent, but is difficult to harness safely if given systemically. Local gene transfer aims to confine the effects of IL12 to malignant tissues, thus avoiding toxicity. Lipid-nanoparticle mRNA achieves IL12 expression and efficacy in mouse models, opening the...

Descripción completa

Detalles Bibliográficos
Autores: Cirella, A. (Assunta)|||/items/398b3896-8ce3-4831-8ebc-1d86487cd790, Berraondo-López, P. (Pedro)|||/items/b1f8ccc3-8e08-4ece-967c-64ccfc0e5b91, Di-Trani, C.A. (Claudia Augusta)|||/items/5d899126-779d-4c97-8232-95bfe18f9f26, Melero, I. (Ignacio)|||/items/82113ea8-7ce1-49d5-9ee3-42cf20db1c4e
Tipo de recurso: artículo
Fecha de publicación:2020
País:España
Institución:Universidad de Navarra
Repositorio:Dadun. Depósito Académico Digital de la Universidad de Navarra
Idioma:inglés
OAI Identifier:oai:dadun.unav.edu:10171/63353
Acceso en línea:https://hdl.handle.net/10171/63353
Access Level:acceso abierto
Palabra clave:Interleukin-12
Immunotherapy
Lipid-nanoparticle mRNA
Descripción
Sumario:IL12 is a very potent cancer immunotherapy agent, but is difficult to harness safely if given systemically. Local gene transfer aims to confine the effects of IL12 to malignant tissues, thus avoiding toxicity. Lipid-nanoparticle mRNA achieves IL12 expression and efficacy in mouse models, opening the way to an ongoing trial.